Recently, on clinicaltrials.gov, Merck & Co Inc MRK posted a new trial of Moderna Inc’s MRNA V940, an individualized neoantigen therapy (INT), plus pembrolizumab for…
Moderna Inc MRNA shares are trading higher after the company reported fourth-quarter 2023 revenues of $2.81 billion in Spikevax (COVID-19 vaccine),…
Moderna Inc MRNA will be reporting its fourth-quarter earnings on Feb. 22. Wall Street expects a negative 99 cents in…
Moderna Inc MRNA shares are trading lower after a longer-term trial analysis revealed a faster decline in the effectiveness of its…